A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, (15902-15907) DOI: 10.1073/pnas.0807840105);A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 41, 2008, Pages 15902-15907

  Capell, Brian C ^a,b   Olive, Michelle ^a   Erdos, Michael R ^a   Cao, Kan ^a   Faddah, Dina A ^a   Tavarez, Urraca L ^a   Conneely, Karen N ^c   Qu, Xuan ^a   San, Hong ^a   Ganesh, Santhi K ^a   Chen, Xiaoyan ^a   Avallone, Hedwig ^d   Kolodgie, Frank D ^d   Virmani, Renu ^d   Nabel, Elizabeth G ^a,e   Collins, Francis S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CVPATH INSTITUTE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Aging; Atherosclerosis; Hutchinson gilford progeria syndrome; Lamin; Translation

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; ASCENDING AORTA; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL LOSS; CONTROLLED STUDY; DESCENDING AORTA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL MODEL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGERIA; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

EID: 57349159315     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907672106     Document Type: Erratum

References (32)

1. Meredith MA, et al. (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358:592-604.
2. Eriksson M, et al. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423:293-298.
3. De Sandre-Giovannoli A, et al. (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 300:2055.
4. Capell BC, Collins FS (2006) Human laminopathies: nuclei gone genetically awry. Nat Rev Genet 7:940-952.
5. Dechat T, et al. (2007). Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci USA 104:4955-4960.
6. Beck LA, Hosick TJ, Sinensky M (1990) Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 110:1489-1499.
7. Varga R, et al. (2006) Progressive vascular smooth muscle cell defects in amouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 103:3250-3255.
8. Capell BC, Collins FS, Nabel EG (2007) Mechanisms of cardiovascular disease in accelerated aging syndromes. Circ Res 101:13-26.
9. Stehbens WE, Delahunt B, Shozawa T, Gilbert-Barness E (2001) Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc Pathol 10:133-136.
10. Lin F, Worman HJ (1993) Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 268:16321-16326.
11. Hennekes H, Nigg EA (1994) The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci 107(Pt 4):1019-1029.
12. Goldman RD, et al. (2004) Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 101:8963-8968.
13. Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11:440-445.
14. Cao K, Capell BC, Erdos MR, Djabali K, Collins FS (2007) A lamin A protein isoform overexpressed in Hutchinson-Gilford progeria syndrome interferes with mitosis in progeria and normal cells. Proc Natl Acad Sci USA 104:4949-4954.
15. Csoka AB, et al. (2004) Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell 3:235-243.
16. Capell BC, et al. (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 102:12879-12884.
17. Toth JI, et al. (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 102:12873-12878.
18. Glynn MW, Glover TW (2005) Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 14:2959-2969.
19. Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S (2005) Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 102:14416-14421.
20. Fong LG, et al. (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311:1621-1623.
21. Yang SH, et al. (2006) A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 116:2115-2121.
22. Basso AD, Kirschmeier P, Bishop WR (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47:15-31.
23. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH (2000) Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 6:2318-2325.
24. Widemann BC, et al. (2006) Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 24:507-516.
25. Scaffidi P, Misteli T (2008) Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 10:452-459.
26. Gordon LB, et al. (2007) Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics 120:824-833.
27. Kieran MW, Gordon L, Kleinman M (2007) New approaches to progeria. Pediatrics 120:834-841.
28. Varela I, et al. (2008) Combined treatment with statins and aminobisphosphonates extends longevity in amouse model of human premature aging. Nat Med 14:767-772.
29. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930-942.
30. Sugita M, Sugita H, Kaneki M (2007) Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27:1390-1395.
31. Scaffidi P, Misteli T (2006) Lamin A-dependent nuclear defects in human aging. Science 312:1059-1063.
32. McClintock D, et al. (2007) The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS ONE 2:e1269.